SCHEMBL4228293

SCHEMBL4228293

CCCCCCCNC(=O)N(C)c1cccc(-c2ccc(/C=C\C(=O)O)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.49
SELP P16109 6/20 0.48
SELE P16581 2/20 0.42
APP P05067 1/20 0.42
PTGS2 P35354 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ESR1 P03372 2/20 0.40
ESR2 Q92731 2/20 0.40
GAA P10253 1/20 0.39
BCHE P06276 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083411 1.00 EGFR (0.49) EGFRSELPSELEAPPPTGS2
SCHEMBL2083408 1.00 EGFR (0.49) EGFRSELPSELEAPPPTGS2
SCHEMBL2085821 0.99 EGFR (0.47) EGFRSELPSELEAPPPTGS2
SCHEMBL2085824 0.99 EGFR (0.47) EGFRSELPSELEAPPPTGS2
SCHEMBL2086347 0.92 GAA (0.41) SELPKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2086345 0.92 GAA (0.41) SELPKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2083272 0.91 EGFR (0.48) EGFRSELPSELEAPPPTGS2
SCHEMBL4610892 0.91 EGFR (0.48) EGFRSELPSELEAPPPTGS2
SCHEMBL2083275 0.91 EGFR (0.48) EGFRSELPSELEAPPPTGS2
SCHEMBL4610891 0.91 EGFR (0.48) EGFRSELPSELEAPPPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA EGFR 755/4885SELP 3757/4885SELE 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.